Lilly agrees to acquire obesity drug maker Versanis Bio for $1.925bn
Eli Lilly and Co. (Lilly) has signed a definitive agreement to acquire Versanis Bio, a clinical-stage biopharmaceutical company focused on developing treatments for cardiometabolic diseases. Under the terms